Trial reportJournal of neurology2006
Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.
Trial report in Journal of neurology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 10 syntheses or guidelines pooled it, 171 citations in OpenAlex.
- Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials.British journal of clinical pharmacology · 2026Pooled it
- Pooled it
- Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis.PloS one · 2023Pooled it
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- Cys-loop receptors on cannabinoids: All high?Frontiers in physiology · 2022Pooled it
- Cannabinoid Activity-Is There a Causal Connection to Spasmolysis in Clinical Studies?Biomolecules · 2021Pooled it
- Analgesic Effects of Cannabinoids for Chronic Non-cancer Pain: a Systematic Review and Meta-Analysis with Meta-Regression.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020Pooled it
- Cannabis-based medicines for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials.British journal of clinical pharmacology · 2011Pooled it
- Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review.BMC neurology · 2009Pooled it
- Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial.The journal of headache and pain · 2012Trial
- Radical Revelations: The Interplay of Nitrosative Stress, the Endocannabinoid System, and Treatment of Age-Related Disorders.International journal of molecular sciences · 2026Review
- Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- Cannabinoids in neuropathic pain treatment: pharmacological insights and clinical outcomes from recent trials.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Comparative targeted lipidomics between serum and cerebrospinal fluid of multiple sclerosis patients shows sex and age-specific differences of endocannabinoids and glucocorticoids.Acta neuropathologica communications · 2024Article
- Review
- Exploring the versatile roles of the endocannabinoid system and phytocannabinoids in modulating bacterial infections.Infection and immunity · 2024Review
- Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality.International journal of molecular sciences · 2024Review
- Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease.NPJ Parkinson's disease · 2024Article
- Axially Chiral Cannabinoids: Design, Synthesis, and Cannabinoid Receptor Affinity.Journal of the American Chemical Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 30% of patients with chronic upper motor neuron syndrome (UMNS) suffer from disabling spasticity-related pain not sufficiently correctable by conventional treatment. Delta9-tetrahydrocannabinol (Delta(9)-THC) was reported to add benefit in the treatment of pain in patients with multiple sclerosis (MS). The question arose whether synthetic cannabinoids with lower potential for psychotropic side effects could be effective as well. To evaluate the safety and efficacy of low dose treatment with the synthetic cannabinoid Nabilone (1 mg per day) on spasticity-related pain a placebo-controlled double-blind crossover trial was performed.11 out of 13 included patients completed the study. The 11-Point-Box-Test showed a significant decrease of pain under Nabilone (p < 0.05), while spasticity, motor function and activities of daily living did not change. 5 patients reported side effects: one moderate transient weakness of the lower limbs (Nabilone phase, drop out), three mild drowsiness (two Nabilone, one placebo) and one mild dysphagia (placebo). One patient was excluded from the study due to an acute relapse of multiple sclerosis (Nabilone phase, drop out). Nabilone 1 mg per day proved to be a safe and easily applicable option in the care of patients with chronic UMNS and spasticity-related pain otherwise not controllable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.